James D. (Jim) Neaton's Research

Biological & Clinical Efficacy of Subcutaneous Recombinant Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: Novartis Pharmaceuticals Corporation
Biological & Clinical Efficacy of Subcutaneous Recombinant Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy

Coordinating Center for SILCAAT Study

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: Chiron and the National Institutes of Health

ESPRIT Research Support

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: Novartis Pharmaceuticals Corporation
ESPRIT Research Support

Flu Study

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: Science Applications International Corp.
Flu Study

GBV-C effects on CD4 activation and expansion

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: The University of Iowa
GBV-C effects on CD4 activation and expansion

INSIGHT Admin Supplement: Biomarker Studies on the Patho

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: NIH Nat'l Inst of Allergy & Infect Dis
INSIGHT Admin Supplement: Biomarker Studies on the Patho

INSIGHT Leadership Group

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: NIAID, NIH
The International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) is a worldwide collaborative clinical trials network that conducts research in the area of optimization of HIV management and co-morbidities. Background: INSIGHT is a merger of two existing clinical trials research groups, ESPRIT (Evaluation of Subcutaneous Proleukin? in a Randomized Clinical Trial) established in 1999 and the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) established in 1989 which initiated the Strategies for Management of Antiretroviral Therapy (SMART) study in 2002. The network is currently conducting research in 36 countries. INSIGHT??s mission is to conduct studies in the area of optimization of clinical management of HIV, including co-morbidities. INSIGHT will evaluate strategies for using antiretroviral therapies (ART) and immunomodulatory therapies and study interventions to prevent and treat complications of HIV and ART in order to prolong disease-free survival in a demographically, geographically, and socio-economically diverse population of individuals infected with HIV. INSIGHT will conduct large randomized trials with morbidity and mortality outcomes, preceded, where appropriate, by vanguard (smaller pilot) studies to refine design parameters. INSIGHT studies will be designed to be relevant to both resource-abundant and resource-constrained countries. Studies will be directed at understanding how to minimize the adverse effects of long-term treatment, while maximizing treatment benefits. Sub-studies will be conducted as part of larger trials. The large trials conducted by INSIGHT also provide a significant body of data for epidemiological analyses using the combined database of several trials. In addition, nested case-control studies that take advantage of the large cross-study database with clinical outcomes and the associated specimen repositories will be carried out. INSIGHT plans to foster relationships with other the networks, other institutes at NIH, and international groups in order to maximize efficiency and research productivity. Trials carried out by INSIGHT will help inform clinical practice.

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: NIH Nat'l Inst of Allergy & Infect Dis
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: NIH Nat'l Inst of Allergy & Infect Dis
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)

International Trial of IL-2

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: NIAID, NIH
ESPRIT is an international trial to determine whether subcutaneous IL-2 delays progression to AIDS and extends survival among HIV infected individuals taking antiretroviral therapy. A total of 4,150 patients have been enrolled are being followed by several hundred sites in 25 countries. ESPRIT funding and management is now part of INSIGHT.

Statistical Center and Data Management Center for Community Programs for Clinical Research on AIDS

Principal Investigator: James D. (Jim) Neaton
Investigators:
Funding Agency: NIAID, NIH
The Community Programs for Clinical Research on AIDS (CPCRA) evaluates strategies to treat HIV in sites that provide HIV primary care. Over 50 major trials have been conducted. CPCRA funding and management is now part of INSIGHT.

Strategic Timing of AntiRetroviral Treatment Bone Mineral Density Substudy (START BMD)

Principal Investigator: James D. (Jim) Neaton
Investigators: Kristine Ensrud
Funding Agency: National Institute of Allergy and Infectious Diseases (NIAID)

The main goal of this substudy is to examine the effect of untreated HIV versus early antiretroviral therapy on bone mineral density in HIV-infected adults with high CD4 cell counts.